Selective mRNA translation in developmental disorders

发育障碍中的选择性 mRNA 翻译

基本信息

批准号：
10197974
负责人：
Slobodan Beronja
金额：
$ 43.32万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-18 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10197974
关键词：
5&apos Untranslated Regions Affect Biochemical Biological Assay Cell Differentiation process Cells Complex Congenital Abnormality Congenital Disorders Costello syndrome Coupled DNA Data Defect Development Diamond Diamond-Blackfan anemia Dysmorphology EIF2B5 gene Elements FBXO32 gene Family Genes Genetic Genetic Screening Genetic Translation Genomics Germ-Line Mutation Goals Growth Growth Disorders Guanine Homeostasis Housekeeping Hyperactivity Impairment Individual Innovative Therapy Investigation Knowledge Laboratories Lead Left Life Light Link MAP Kinase Gene Malignant Neoplasms Mandibulofacial Dysostosis Mediating Messenger RNA Mitotic Modeling Molecular Morbidity - disease rate Musculoskeletal Mutation Names Noonan Syndrome Normal tissue morphology Pathologic Pathology Pathway interactions Patients Peptide Initiation Factors Phenotype Predisposition Protein Biosynthesis Psyche structure RAS genes RNA Regulon Skin Skin Abnormalities Syndrome Testing Therapeutic Tissue Expansion Tissue Model Tissues Transcript Translation Initiation Translations Ubiquitination United States base cardiofaciocutaneous syndrome craniofacial design developmental disease epidermal stem cell gene function genome-wide analysis in vivo in vivo Model in vivo imaging innovation insight intravital imaging intravital microscopy malformation member mouse model novel novel therapeutic intervention novel therapeutics progenitor programs rapid growth ribosome profiling self-renewal stem cell biology stem cell proliferation stem cells ubiquitin ligase ubiquitin-protein ligase

5&apos Untranslated Regions Affect Biochemical Biological Assay Cell Differentiation process Cells Complex Congenital Abnormality Congenital Disorders Costello syndrome Coupled DNA Data Defect Development Diamond Diamond-Blackfan anemia Dysmorphology EIF2B5 gene Elements FBXO32 gene Family Genes Genetic Genetic Screening Genetic Translation Genomics Germ-Line Mutation Goals Growth Growth Disorders Guanine Homeostasis Housekeeping Hyperactivity Impairment Individual Innovative Therapy Investigation Knowledge Laboratories Lead Left Life Light Link MAP Kinase Gene Malignant Neoplasms Mandibulofacial Dysostosis Mediating Messenger RNA Mitotic Modeling Molecular Morbidity - disease rate Musculoskeletal Mutation Names Noonan Syndrome Normal tissue morphology Pathologic Pathology Pathway interactions Patients Peptide Initiation Factors Phenotype Predisposition Protein Biosynthesis Psyche structure RAS genes RNA Regulon Skin Skin Abnormalities Syndrome Testing Therapeutic Tissue Expansion Tissue Model Tissues Transcript Translation Initiation Translations Ubiquitination United States base cardiofaciocutaneous syndrome craniofacial design developmental disease epidermal stem cell gene function genome-wide analysis in vivo in vivo Model in vivo imaging innovation insight intravital imaging intravital microscopy malformation member mouse model novel novel therapeutic intervention novel therapeutics progenitor programs rapid growth ribosome profiling self-renewal stem cell biology stem cell proliferation stem cells ubiquitin ligase ubiquitin-protein ligase

展开

项目摘要

Abstract RASopathies cause the majority of congenital disorders affecting nearly 1 in 1000 individuals. In particular, mutations in RAS-MAPK pathway genes lead to distinct pathologies including craniofacial dysmorphology, mental impairment, musculoskeletal defects, and a predisposition to cancer. Although presentations may vary between different mutations, nearly all RASopathies share common skin growth abnormalities. At a genetic level, germline mutations to RAS pathway members including Hras and Kras are known to cause these defects which are best exemplified by Costello, Noonan, and Cardiofaciocutaneous syndromes. For years, comprehensive interrogation of RAS in development has been limited to genome-wide studies of DNA and RNA. While important, these investigations have left translation-based mechanisms largely untouched. This is remarkable in light of emerging evidence that developmental disorders, such as Diamond-Blackfan Anemia and Schwachman-Diamond and Treacher Collins syndromes (reviewed in Tahmasebi et al., 2018), are causally linked to impairments in the translation apparatus. Thus, our current knowledge of the mechanistic basis of RASopathies is incomplete, which is a barrier to therapeutic innovation. Our long-term goal is to uncover the mechanism of Ras-mediated tissue growth, which will ultimately yield innovative therapies to restore normal tissue homeostasis without compromising housekeeping functions during development. Using skin as a defined model of tissue development we have discovered that hyperactive Hras simultaneously drives specialized proliferation and differentiation programs by rewiring the translation initiation machinery through eIF2B5. Utilizing state-of-the-art in vivo genetic screens pioneered in our laboratory, we have determined the regulon of genes that eIF2B5 governs to impact self-renewal and cell fate choice. Remarkably, these mRNA networks are clearly demarcated by their function with ubiquitination emerging as a key regulator of cellular differentiation. As such, we hypothesize that activation of Ras promotes translation of a subset of mRNAs that support non-physiological tissue growth during development, where increased stem cell proliferation is balanced by their loss through differentiation into post-mitotic progeny. In this proposal we will use a confluence of in vivo models, intra-vital microscopy, and newly developed cellular and molecular assays to delineate how the interplay between RAS and eIF2B5 influences tissue dynamics. We will accomplish the following Aims: 1) Uncover how eIF2B5-dependent ubiquitin ligases directs progenitor renewal and fate choice; and 2) Elucidate how activated Hras and eIF2B5 direct mRNA specific translation to regulate progenitor renewal. Collectively, the successful completion of our Aims will provide a new understanding of cellular and molecular principles that support Ras-driven non-physiological growth during development. Ultimately, these new insights will inform the development of novel therapeutics, which can differentially inhibit the pathologic impact of Ras mediated tissue imbalance while maintain homeostasis which is essential for life.

抽象的 rasopathies导致大多数影响近1000名患者的先天性疾病。尤其， RAS-MAPK途径基因中的突变导致不同的病理，包括颅面畸形，精神障碍，肌肉骨骼缺陷和癌症的易感性。尽管演讲可能会有所不同在不同的突变之间，几乎所有的ras病都有常见的皮肤生长异常。在遗传上水平，已知包括HRA和KRA在内的RAS途径成员的种系突变会导致这些缺陷最好用Costello，Noonan和Cardiofaciociatanous综合征来体现。多年来，对RAS开发中RA的全面询问仅限于全基因组的DNA和 RNA。尽管很重要，但这些研究使基于翻译的机制在很大程度上没有受到影响。这是鉴于新兴的证据表明发育障碍，例如钻石 - 黑人贫血以及Schwachman-Diamond和Treacher Collins综合征（在Tahmasebi等人，2018年进行了评论），是与翻译机构中的损害有因果关系。因此，我们当前对机械的知识消除病是不完整的，这是治疗创新的障碍。我们的长期目标是发现RAS介导的组织生长的机制，最终将产生创新的疗法恢复正常的组织稳态，而不会在发育过程中损害家政功能。使用皮肤作为组织开发的定义模型，我们发现同时过度活跃的HRA 通过重新布线翻译启动机械来驱动专业的扩散和差异化计划通过EIF2B5。利用在我们实验室开创的体内遗传筛选中，我们有确定了EIF2B5控制自我更新和细胞命运选择的基因的调节。值得注意的是这些mRNA网络清楚地通过泛素化作为关键调节剂的泛素化功能来划分细胞分化。因此，我们假设RAS的激活促进了一部分的翻译支持在发育过程中非生理组织生长的mRNA，其中干细胞增加通过分化为有丝分裂后后代的损失，增殖是平衡的。在这个建议中，我们将使用体内模型，重要内显微镜以及新开发的细胞和分子测定的汇合描绘RAS和EIF2B5之间的相互作用如何影响组织动力学。我们将完成以下目的：1）发现依赖EIF2B5的泛素连接酶如何指导祖细胞更新和命运选择； 2）阐明如何激活的HRA和EIF2B5直接mRNA特异性翻译以调节祖细胞更新。总体而言，我们的目标的成功完成将提供对蜂窝的新理解和在开发过程中支持RAS驱动的非生理生长的分子原理。最终，这些新的见解将为新型治疗学的发展提供信息，这可以差异地抑制病理学 RAS介导的组织失衡的影响，同时保持体内平衡，这对生命至关重要。